Liu Z Y, Zhang S J, Yan Z Y, Sun H M, Chen Y B
Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201800, China.
Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):269-272. doi: 10.3760/cma.j.cn121090-20240611-00219.
This study aimed to investigate the efficacy and safety of blinatumomab in adult patients with acute B-lymphoblastic leukemia (B-ALL) by conducting a retrospective analysis of the clinical data from 16 patients with B-ALL receiving blinatumomab at the Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, from June 2022 to April 2024. Among the 16 patients, 10 were classified as relapsed/refractory B-ALL and 6 were newly diagnosed Ph(-) B-ALL. Of the 10 patients with relapsed/refractory B-ALL, 8 achieved complete remission (CR) and minimal residual disease (MRD) negativity after one blinatumomab treatment cycle. In the 6 newly diagnosed patients, the bone marrow MRD was negative after one blinatumomab treatment cycle after initial induction chemotherapy followed by sequential blinatumomab treatment. Among them, four completed allogeneic hematopoietic stem cell transplantation and continuously maintained CR. This indicates that blinatumomab exhibits a high remission rate in both patients with relapsed/refractory and newly diagnosed B-ALL, thereby providing the possibility of bridging to transplantation and extending patient survival, with manageable adverse reactions.
本研究旨在通过对2022年6月至2024年4月在上海交通大学医学院附属瑞金医院接受贝林妥欧单抗治疗的16例B淋巴细胞白血病（B-ALL）成年患者的临床资料进行回顾性分析，探讨贝林妥欧单抗治疗成人急性B淋巴细胞白血病（B-ALL）的疗效和安全性。16例患者中，10例为复发/难治性B-ALL，6例为新诊断的Ph(-) B-ALL。10例复发/难治性B-ALL患者中，8例在一个贝林妥欧单抗治疗周期后达到完全缓解（CR）且微小残留病（MRD）阴性。6例新诊断患者在初始诱导化疗后序贯使用贝林妥欧单抗治疗，一个治疗周期后骨髓MRD为阴性。其中4例完成了异基因造血干细胞移植并持续维持CR。这表明贝林妥欧单抗在复发/难治性和新诊断的B-ALL患者中均显示出高缓解率，从而为过渡到移植和延长患者生存期提供了可能，且不良反应可控。
